- MorphoSys AG's MOR partner Roche Holdings AG RHHBY announced results from the GRADUATE I and II studies evaluating gantenerumab in mild cognitive impairment (MCI) due to Alzheimer's and mild Alzheimer's dementia.
- The studies did not meet their primary endpoint of slowing clinical decline.
- Gantenerumab was well tolerated, including the subcutaneous administration.
- The level of beta-amyloid removal, the protein that builds up to make plaques in the brains of people with Alzheimer's disease, was lower than expected.
- Gantenerumab showed a slowing of clinical decline in GRADUATE I and GRADUATE II of -0.31 and -0.19, respectively, from baseline. However, neither was statistically significant.
- This represents a relative reduction in the clinical decline of 8% in GRADUATE I and 6% in GRADUATE II compared with placebo.
- The GRADUATE Phase 3 program evaluated gantenerumab over 27 months in over 1,900 participants.
- In July, Roche's other Alzheimer's medicine, crenezumab did not slow or prevent cognitive decline in people with a specific genetic mutation that causes early-onset disease.
- In September 2000, MorphoSys collaborated with Roche.
- MorphoSys is entitled to receive tiered royalties, ranging from 5.5% to 7.0%, on net product sales and potential success-based regulatory milestone payments related to gantenerumab.
- MorphoSys will retain 40% of future royalties on gantenerumab and pass 60% to Royalty Pharma.
- Price Action: MOR shares are down 29.30% at $3.86 during the premarket session on the last check Monday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Posted In:
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
